Company
About us
Acticor Team
Board of Directors
investors & Partners
Prizes & Awards
Our Product
Our product: Glenzocimab
GPVI / GLENZOCIMAB in brief
in acute ischemic stroke
⮑ Positive results actimis study
in other indications
Pipeline
About stroke
Key figures
What is a stroke?
Media
Press Releases
Publications
Media Coverage
Events
Investors
Welcome
Corporate Presentation
Share Overview
Shareholders' Meeting
Regulated Information
Financial Agenda
COntact
Investors
Press Releases
March 9, 2023
Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares